LOUISVILLE, Ky., July 05, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds) announces ZIMHIâ„¢ (naloxone HCL Injection) 5mg/0.5mL is now available for ordering by public interest groups through the...
LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and...
LOUISVILLE, Ky., Aug. 31, 2021 /PRNewswire/ -- US WorldMeds, a Kentucky-based specialty pharmaceutical company, announced Walgreens will stock LUCEMYRA (lofexidine) tablets in Walgreens pharmacies across the U.S., effective September 1. LUCEMYRA is the only FDA-approved, non-opioid, non-addictive treatment for relief of multiple symptoms of opioid withdrawal in adults and requires a valid prescription to be dispensed.1 Eligible patients covered by commercial insurance will pay $0* for a LUCEMYRA prescription. Patients without insurance coverage for LUCEMYRA may be eligible to pay $300 for a LUCEMYRA prescription.
ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the closing of the acquisition of the CNS portfolio of US WorldMeds, a privately-held biopharmaceutical company. This transaction builds on Supernus’ experience in CNS diseases and expands its marketing and development efforts into Parkinson’s disease.